Evidence map›Paper›PMID 39770907›Full record

ReviewNutrients2024

From Structure to Function: How Prebiotic Diversity Shapes Gut Integrity and Immune Balance.

Lucas de Freitas Pedrosa, Paul de Vos, João Paulo Fabi

Abstract readReview
In one paragraph

Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lucas de Freitas PedrosaDepartment of Food Science and Experimental Nutrition, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-000, SP, Brazil.ORCID 0000-0003-2053-0407
Paul de VosDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.ORCID 0000-0001-9618-2408
João Paulo FabiDepartment of Food Science and Experimental Nutrition, School of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-000, SP, Brazil.ORCID 0000-0002-7430-7756

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/08063-5 2022/12253-0 2013/07914-8 2022/12834-2National Council for Scientific and Technological Development 307842/2022-3
6 · The paper itself

Abstract

The microbiota stability, diversity, and composition are pillars for an efficient and beneficial symbiotic relationship between its host and itself. Microbial dysbiosis, a condition where a homeostatic bacterial community is disturbed by acute or chronic events, is a predisposition for many diseases, including local and systemic inflammation that leads to metabolic syndrome, diabetes, and some types of cancers. Classical dysbiosis occurs in the large intestine. During this period, pathogenic strains can multiply, taking advantage of the compromised environment. This overgrowth triggers an exaggerated inflammatory response from the human immune system due to the weakened integrity of the intestinal barrier. Such inflammation can also directly influence higher polyp formation and/or tumorigenesis. Prebiotics can be instrumental in preventing or correcting dysbiosis. Prebiotics are molecules capable of serving as substrates for fermentation processes by gut microorganisms. This can promote returning the intestinal environment to homeostasis. Effective prebiotics are generally specific oligo- and polysaccharides, such as FOS or inulin. However, the direct effects of prebiotics on intestinal epithelial and immune cells must also be taken into consideration. This interaction happens with diverse prebiotic nondigestible carbohydrates, and they can inhibit or decrease the inflammatory response. The present work aims to elucidate and describe the different types of prebiotics, their influence, and their functionalities for health, primarily focusing on their ability to reduce and control inflammation in the intestinal epithelial barrier, gut, and systemic environments.

Indexed as

Gastrointestinal TractPrebioticsAnimalsDysbiosisGastrointestinal MicrobiomeHomeostasisHumansInflammationIntestinal MucosaPrebioticsdysbiosisinflammationmicrobiotapolysaccharidesprebiotics

Identifiers

PMID39770907
PMCPMC11678351

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.